Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Riner

Nurse Practitioner, Family Crab Orchard, WV Nurse Practitioner

NPI 1255003836 CMS profile 11270094

1404 Robert C Byrd Dr Ste 100, Crab Orchard, WV 25827

Open in the dashboard

General payments

$9,456

493 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Riner of Crab Orchard, WV is reported in the CMS Open Payments database as having received $9,456 across 493 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,128 170
2024 General $2,395 119
2023 General $2,238 108
2022 General $1,393 81
2021 General $302 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Riner
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Melissa Riner were reported at $3,128. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Melissa Riner Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $302 $124 $35–$379 $132
2022 $1,393 $141 $44–$430 $149
2023 $2,238 $154 $49–$476 $160
2024 $2,395 $165 $51–$504 $164
2025 $3,128 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alexion Pharmaceuticals, Inc. $1,229 38 payments
  2. Pfizer Inc. $811 62 payments
  3. AbbVie, Inc. $753 46 payments
  4. Novartis Pharmaceuticals Corporation $644 34 payments
  5. Biogen, Inc. $538 35 payments
  6. SK Life Science, Inc. $514 24 payments
  7. Argenx US, Inc. $494 24 payments
  8. UCB, Inc. $418 19 payments
  9. Teva Pharmaceuticals USA, Inc. $413 22 payments
  10. Lilly USA, LLC $389 21 payments
  11. Other $3,254 168 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,945 484 payments
  2. Education $511 9 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $811 62 payments
  2. ZAVZPRET $730 58 payments
  3. ULTOMIRIS $729 25 payments
  4. UBRELVY $559 36 payments
  5. KESIMPTA $541 28 payments
  6. QULIPTA $486 34 payments
  7. VYVGART Hytrulo $331 15 payments
  8. VALTOCO $292 15 payments
  9. EMGALITY $288 15 payments
  10. VUMERITY $280 21 payments
  11. Other $5,246 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

493 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record